Page last updated: 2024-08-17

levodopa and n-(3-fluorophenyl)-1-((4-(((3s)-3-methyl-1-piperazinyl)methyl)phenyl)acetyl)-4-piperidinamine

levodopa has been researched along with n-(3-fluorophenyl)-1-((4-(((3s)-3-methyl-1-piperazinyl)methyl)phenyl)acetyl)-4-piperidinamine in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Barton, ME; Burn, DJ; Dukes, GE; Gibson, RA; Hellström, PM; Marrinan, SL; Nyholm, D; Otiker, T; Richards, DB; Sarai, BK; Vasist, LS	1

Trials

1 trial(s) available for levodopa and n-(3-fluorophenyl)-1-((4-(((3s)-3-methyl-1-piperazinyl)methyl)phenyl)acetyl)-4-piperidinamine

Article	Year
A randomized, double-blind, placebo-controlled trial of camicinal in Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society, 2018, Volume: 33, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antiparkinson Agents; Area Under Curve; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Piperazines; Piperidines; Statistics, Nonparametric; Treatment Outcome	2018

Article

Year

A randomized, double-blind, placebo-controlled trial of camicinal in Parkinson's disease.

Movement disorders : official journal of the Movement Disorder Society, 2018, Volume: 33, Issue:2

Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antiparkinson Agents; Area Under Curve; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Piperazines; Piperidines; Statistics, Nonparametric; Treatment Outcome

2018